b'SIU EVENTSB2B Uro-Oncology: GU Cancers TriadHosted in conjunction with 42nd Congress of the SIUABOUT THE MEETINGThe treatment of GU malignancies has seen tremendous evolution in recent years. Prostate cancer, bladder cancer, and renal cell carcinoma are the most frequently encountered GU malignancies and represent a heterogeneous population of cancers, in both histology and approach to treatment. These three cancers continue to undergo major paradigm shifts in their respective therapeutic landscapes as we expand our understanding of their underlying molecularand oncogenic mechanisms.B uilding on the success The B2B GU Cancers Triad meetingAT A GLANCEof the first threeprogramme will enhance the target editions of the GUaudiences understanding of the latest Cancers Triad Meetingtrends in diagnostic modalities andDates: Friday, November 11, 2022in 2019, 2020, andtreatment approaches, and includeVenue: Palais des congrs de Montral2021, the SIU willa discussion of the challenges and convene a follow-up hybrid meetingopportunities that new therapeuticRegistration Rates: Included when you(in-person and virtual) during theapproaches in these fields offer.register for SIU 2022 (see page 9) ; day-only 42nd Congress of the SIU. TheAttendees can also participate in anrates available (November 11)SIU 2022 Congress will be held ininteractive panel discussion to facilitateMore Information: https://www.siu-urology.Montreal, Canada, from November 9understanding of how advances inorg/congress-2022/highlightsto 13, 2022. For one full day, world- diagnosis and treatment can best be renowned experts will focus on theintegrated into patient care.Get the Latest: Follow @SIU_Urology on Twitter latest research in the top three GUand search #B2BGUCancerTriad for updates!cancers: bladder, kidney, and prostate.www.siu-urology.org 11'